Clinical Trial: Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07243691) titled 'Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma' on Sept. 08.

Brief Summary: Study on the therapeutic effect of different infusion times on tislelizumab in high-risk postoperative hepatocellular carcinoma

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma

Intervention: DRUG: Tislelizumab: 200mg, intravenous infusion, Q3W

Postoperative adjuvant therapy (maximum of 8 cycles, each cycle lasting 21 days):

- Tislelizumab: 200 mg, intravenous infusion, Q3W.

Based on previous preclinical and clinical studies on cir...